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Abstract  1 
Background: Numerous stem cell therapies use injection-based administration to deliver high density 2 
cell preparations. However, cell retention rates as low as 1% have been observed within days of 3 
transplantation. This study investigated the effects of varying administration and formulation parameters 4 
of injection-based administration on cell dose recovery and differentiation fate choice of human 5 
mesenchymal stem cells.  6 
Methods: The impact of ejection rate via clinically-relevant Hamilton micro-syringes and biomaterial-7 
assisted delivery was investigated. Cell viability, the percentage of cell dose delivered as viable cells, 8 
proliferation capacity as well as differentiation behaviour in bipotential media were assessed. 9 
Characterisation of the biomaterial-based cell carriers was also carried out.  10 
Results: A significant improvement of in vitro dose recovery in cells co-ejected with natural biomaterials 11 
was observed, with ejections within 2% (w/v) gelatin resulting in 87.5±14% of the cell dose being 12 
delivered as viable cells, compared to 32.2±19% of the dose ejected in the commonly-used saline 13 
vehicle at 10 µL/min. Improvement in cell recovery was not associated with rheological properties of 14 
biomaterials utilised, as suggested by previous studies. The extent of osteogenic differentiation was 15 
shown to be substantially altered by choice of ejection rate and cell carrier, despite limited contact time 16 
with cells during ejection. Collagen type I and bone-derived extracellular matrix cell carriers yielded 17 
significant increases in mineralised matrix deposited at day 21 relative to PBS.  18 
Conclusions: An enhanced understanding of how administration protocols and biomaterials influence 19 
cell recovery, differentiation capacity and choice of fate will facilitate the development of improved 20 
administration and formulation approaches to achieve higher efficacy in stem cell transplantation. 21 
Keywords: biomaterials, cell therapy, cell fate, differentiation, injectable, mesenchymal stem cells  22 
 23 
1. Background 24 
To date, most clinical trials employing cell-based therapeutics have used injectable delivery of cellular 25 
suspensions in saline vehicles [1-3]. However, cell loss has been observed within the first minutes post-26 
injection [4], with less than 10% of injected cells retained at the site of interest [2, 5]. Consequently, 27 
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increasing the percentage of viable cells delivered and retained post-injection is critical to the future 1 
success of cell transplantation procedures.  2 
 3 
Mesenchymal stem cells (MSCs) have been the focus of numerous pre-clinical and clinical cell therapy 4 
studies [6]. Stem cell fate is regulated by biochemical and biophysical cues from the microenvironment 5 
[7, 8]. As such, an intricate range of environmental effectors, experienced both during the delivery 6 
procedure and post-transplantation, can impact cell function [9]. For example, cells experience various 7 
types of mechanical forces, including shear forces, during flow through a needle [10]. Although shear 8 
stress has been reported to directly influence the fate of undifferentiated stem cells [11, 12], the impact 9 
of mechanical forces experienced during clinically relevant injection procedures upon the differentiation 10 
potential of hMSCs has yet to be investigated.  11 
 12 
Numerous studies have highlighted that the material surrounding a stem cell is vital in determining its 13 
fate [13-15]. Biomaterials can be used as cell delivery vehicles to provide physical support and protection 14 
for cells and stimulate host cell recruitment and differentiation [16]. Naturally-derived biomaterials may 15 
exhibit inherent bioactivity that can facilitate tissue integration. Examples of naturally derived 16 
biomaterials include collagen, which has been shown to support cell growth in 3D cell culture studies 17 
and in vivo [17-21], and tissue derived extracellular matrices (ECM), harvested by decellularisation of 18 
mammalian tissues  [22].  ECM materials retain the inherent bioactivity of the native matrix and  modulate 19 
cell behaviour and promote constructive remodelling in vivo [23]. Other natural biomaterials, such as 20 
protein-based polymers, have found utility as cell carriers as these biomaterials may mimic 21 
characteristics of the natural ECM and influence the growth and fate of transplanted cells [24]. An 22 
example of naturally-derived biomaterials is carboxymethyl cellulose (CMC), a biodegradable 23 
polysaccharide-based polymer with excellent biocompatibility [25, 26].  24 
 25 
With the rising number of clinical trials exploring MSC-based cell therapies, an understanding of the 26 
factors that influence the functionality of cells post-injection is critical. Despite the advantages of 27 
biomaterials as cell transplantation vehicles, saline-based cell carriers still continue to be the carrier of 28 
choice for many cell therapy clinical trials [1-3]. Since physical, chemical and biological factors have an 29 
impact on differentiation behaviour of cells [27], cues caused by variations in cell administration 30 
protocols can contribute to differentiation commitment decisions of MSCs. Our previous work provided 31 
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evidence that ejection of cell suspensions at a low flow rate negatively impacted cell dose recovery, 1 
viability and function [28, 29]. An enhanced understanding of how injectable biomaterials improve cell 2 
dose recovery and influence stem cell differentiation will facilitate the development of improved 3 
administration and formulation approaches to achieve higher efficacy and reduce variability in stem cell 4 
transplantation. The present study aimed to examine the influence of varying cell administration and 5 
formulation parameters on fate choice of hMSCs by (i) assessing the impact of ejection upon the 6 
differentiation capacity of primary human MSCs using clinically-relevant needles and (ii) determining the 7 
potential value of user-friendly injectable biomaterials to improve delivery efficiency and to direct cell 8 
fate.  9 
 10 
2. Methods  11 
 Overall experimental design 12 
The general experimental design for this study is depicted schematically in Supplemental Figure 1. The 13 
first part of this study aimed to determine whether initial cell seeding density influenced differentiation 14 
capacity. This was key to understand whether any impact observed on differentiation capacity would be 15 
related to the number of cells being ejected at the slow flow rates employed [28], or the effect of cell 16 
administration variables under investigation. The second part of the study assessed the impact of 17 
varying ejection rate on the differentiation capacity of ejected cells. Cell dose recovery and differentiation 18 
capacity of hMSCs ejected within various injectable biomaterial-based carriers were examined at low 19 
ejection rates. Differentiation to osteoblastic and adipogenic lineages was examined in bipotential 20 
differentiation ‘mixed’ media, with a formulation designed to induce both. 21 
 Human mesenchymal stem cell culture 22 
Primary human bone marrow mesenchymal stem cells (hMSCs) were obtained from Lonza and cultured 23 
in mesenchymal stem cell growth medium (MSCGM) (Lonza, Cologne, Germany; #PT-3001) with 5% 24 
CO2 in air at 37ºC. Lot numbers of hMSC batches obtained were as follows: #0000351482, 25 
#0000411107, and #0000422610, cultured as individual patient stocks. Cells used in this study were 26 
between the third and fifth passages. These cells were tested for the ability to differentiate into 27 
osteogenic, adipogenic and chondrogenic lineages, and for expression of surface markers 28 
recommended by the International Society for Cellular Therapy (ISCT) [30]. All routine passaging and 29 
differentiation procedures were performed according to Lonza’s Poietics™ hMSCs protocols.  30 
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 1 
 Effects of cell seeding density on differentiation potential of hMSCs 2 
Cell seeding densities tested ranged from 1000-70,000 hMSCs per well in 12-well plates (Nunc, Thermo 3 
Fisher Scientific, UK), equivalent to 0.3-18.4 x 103 cells/cm2. Twenty-four hours after seeding, the 4 
medium was replaced with bipotential differentiation medium, formulated by combining adipogenic (#PT-5 
3004; Lonza, Germany) and osteogenic media (#PT-3002; Lonza, Germany) in a 1:1 ratio. Cultures was 6 
incubated for 21 days. The differentiation medium was changed every 3-4 days for the duration of the 7 
differentiation period. Nuclear-based cell counts were carried out using propidium iodide (PI) staining of 8 
the fixed cells in osteogenesis experiments and using Hoechst 33258 in adipogenesis studies. 9 
 Preparation of hMSCs and ejection protocol 10 
After trypsinisation, cells were centrifuged then reconstituted to a density of 1.4x106 cells/mL in 11 
phosphate buffered saline (PBS) for cell ejection studies, then were mixed 1:1 with either PBS or the 12 
biomaterial-based carrier under investigation (via gentle mixing) to give a final density of 7x105 cells/mL. 13 
Density of cell suspensions used in this study was selected conservatively based on published clinical 14 
studies [31-33] as well as practical considerations. Aliquots (100 µL) of this cell suspension were used 15 
for ejection experiments. Cells were directly pipetted into well plates (not ejected) to provide controls. 16 
For ejection, 100 µL Hamilton GASTIGHT® syringes (model 1710RN), attached to 30G 20mm removable 17 
(RN) stainless steel needles were employed (Hamilton Bonaduz, Switzerland). All ejection studies were 18 
carried out at room temperature. Cell/carrier mixtures were set aside for 20 minutes before ejection, to 19 
represent delay time between loading and injection in cell transplantation procedures [34]. Ejection rates 20 
employed in clinical trials have been variable, ranging from 5 µL/min [35] and up to 1000 µL/min for 21 
stroke [36, 37]. Therefore, ejection rates employed in this study (10-300 µL/min) were selected to 22 
represents a range of clinically relevant ejection rates previously used in clinical trials. Cell suspensions 23 
were drawn up with a Harvard® Infuse/Withdraw syringe pump (PHD 2000, Harvard Apparatus®, MA, 24 
USA) at 300 µL/min through the needle before being ejected at the chosen flow rate into Eppendorf 25 
tubes. Ejected samples were then transferred into the appropriate well plates.  26 
 27 
 Qualitative and quantitative assessment of differentiation capacity of ejected hMSCs 28 
Differentiation to osteoblastic and adipogenic lineages was examined in bipotential ‘mixed’ media (see 29 
2.3). Bipotential medium was added to the cells in 12-well plates at 24 hours post-seeding, and cells 30 
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were alternated between adipogenic induction/osteogenic induction media (1:1) and adipogenic 1 
maintenance/osteogenic media (1:1) every 3-4 days, according to the manufacturer’s instructions, for 2 
21 days.  Uninduced controls were maintained in basal medium MSCGM (#PT-3001; Lonza, Germany). 3 
 4 
2.3.1 Adipogenic differentiation 5 
After 21 days, cultures were rinsed with 70% (v/v) isopropanol for five minutes and differentiation was 6 
qualitatively assessed by specific staining of lipid droplets with 0.5% Oil Red O solution (Sigma-Aldrich, 7 
Poole, UK). Intracellular lipid accumulation was quantified using the AdipoRed™ Adipogenesis Assay 8 
(Lonza, Germany) following the manufacturer's protocol. Briefly, cells were pre-washed with PBS and 9 
incubated with AdipoRed™ Reagent for 10 minutes. Fluorescence was measured using a plate reader 10 
(λexc/λem 485/572 nm). 11 
 12 
2.3.2 Osteogenic differentiation 13 
After 21 days of incubation, cells were fixed in 10% (v/v) formalin. The presence of extracellular calcium 14 
deposits was qualitatively verified using Alizarin Red staining solution (Merck Millipore, UK) and von 15 
Kossa silver staining kit (Merck Millipore, UK). For Alizarin Red staining, cells were treated with Alizarin 16 
Red S for 5 minutes at room temperature. After washing three times in deionised water, cells were 17 
observed microscopically. For von Kossa staining, cells were incubated with silver nitrate solution under 18 
exposure to UV light for 20 minutes. Wells were then washed with deionised water three times, and 19 
treated with sodium thiosulfate solution for 5 minutes. Afterwards, wells were washed three times with 20 
deionised water. Mineralised nodules were visualised as black spots. 21 
 22 
2.3.2.1 OsteoImage staining for quantitation of hydroxyapatite deposition 23 
In vitro mineralisation was assessed by staining the hydroxyapatite portion of mineralised bone nodules 24 
using the OsteoImageTM Mineralisation Assay kit (Lonza, Germany) according to manufacturer 25 
instructions. Briefly, cells were fixed in 10% (v/v) formalin, rinsed twice using the wash buffer, then 26 
stained with the staining solution provided (1:100 dilution in wash buffer) and incubated for 30 minutes. 27 
Following incubation, cells were rinsed three times with wash buffer. This assay allows the assessment 28 
of in vitro mineralisation both visually by fluorescent microscopy and quantitatively using a plate reader 29 
(λexc/λem: 492/520 nm). 30 
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 1 
2.3.2.2 Quantitative alkaline phosphatase staining 2 
For quantitative determination of alkaline phosphatase (ALP) activity, the Fluorometric Alkaline 3 
Phosphatase Assay Kit (#ab83371, Abcam, UK) was used, as per manufacturer’s protocol. Cultured 4 
cells were lysed using three freeze-thaw cell lysis steps. Samples (media or cell lysate) were incubated 5 
with the non-fluorescent 4-methylumbelliferyl phosphate disodium salt (MUP) as a substrate. The 6 
resultant fluorescence was measured using a plate reader. ALP activity was normalised to total DNA 7 
content, measured using the Quant-iT PicoGreen dsDNA Assay Kit (#P11496; Invitrogen, UK). 8 
 9 
2.3.2.3 Osteocalcin (OCN) immunostaining 10 
hMSCs were rinsed with warm PBS and fixed with 3.7 % (w/v) paraformaldehyde in PBS for 20 minutes, 11 
followed by a wash with warm PBS for 5 minutes. Cells were permeabilised using 0.1% (w/v) Triton-X 12 
100 in PBS (Sigma-Aldrich, UK) for 30 minutes. Non-specific binding sites were blocked by incubation 13 
in 10% (v/v) normal donkey serum (D9663, Sigma-Aldrich, UK) and 1% bovine serum albumin (BSA) in 14 
PBS for 1 hour. Cells were then incubated with Mouse Anti-Human Osteocalcin Monoclonal Antibody 15 
(MAB1419, R&D Systems) diluted in 1% (w/v) BSA in PBS at 10 µg/mL for 3 hours at room temperature. 16 
This was followed by two washes with PBS supplemented with 0.1% (w/v) BSA (5 minutes each). The 17 
secondary antibody, a Donkey Anti-Mouse IgG-FITC antibody (NL007, R&D Systems), diluted in 1% 18 
(w/v) BSA in PBS (1:200), was added for 1 hour in the dark, followed by two washes with PBS (5 minutes 19 
each). Samples were counterstained with DAPI NucBlue® Fixed Cell ReadyProbes (ThermoFischer 20 
Scientific, UK) for 5 minutes, then visualised using a Leica DM-IRB inverted microscope (Leica 21 
Microsystems Ltd., UK). 22 
 23 
 Preparation of biomaterial-based carriers for ejection of hMSCs 24 
2.4.1 Carboxymethyl cellulose (CMC)  25 
CMC carriers were prepared using high viscosity CMC (#12M31P, Ashland Speciality Ingredients, 26 
Poole, UK) in tissue culture water at a concentration of 0.5% and 0.25% (w/v). CMC carriers were 27 
sterilised by tyndallisation. Tyndallisation was carried out by heating the prepared solutions three times 28 
at 70°C for 20 min each at 24 hr intervals. 29 
 30 
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2.4.2 Type I collagen 1 
Commercially available high concentration rat-tail collagen type I (#354249, 10 mg/mL, BD Biosciences, 2 
Oxford, UK) was prepared at a concentration of 1.75 mg/mL following manufacturer’s instructions. 3 
Briefly, collagen was freshly prepared for experiments by combining rat-tail collagen type I with 10× 4 
PBS, ice-cold 1N sodium hydroxide, and sterile ice cold deionised water to achieve a final collagen 5 
concentration of 1.75 mg/mL. The solution was mixed and kept at 4°C. 6 
 7 
2.4.3 Bone extracellular matrix (bECM) 8 
Decellularised and demineralised bone ECM was obtained as described previously [38]. Briefly, liquid 9 
nitrogen was used to freeze bovine cancellous bone to facilitate fragmentation. Cancellous fragments 10 
were demineralised using 0.5 M HCl at room temperature for 24 hours. Following demineralisation, a 11 
solution of chloroform/methanol was used to remove lipids then demineralised powder was subjected 12 
to 24 hours of decellularisation in 0.05% Trypsin/0.02% EDTA at 37°C. Powdered bone was combined 13 
with 1 mg/mL pepsin in 0.01 M HCl for a final concentration of 10 mg/mL and this suspension was stirred 14 
for 96 hours. Resultant bECM digests were aliquoted and stored at -20°C until required. Neutralisation 15 
of the required digest volume was carried out by addition of one tenth of the digest volume of NaOH (0.1 16 
N) and one ninth of the digest volume of PBS (10×), then diluting to the desired final bECM concentration 17 
with 1× PBS on ice. A concentration of 1.75 mg/mL bECM was freshly prepared for ejection studies.  18 
 19 
2.4.4 Gelatin 20 
Commercially available 2% (w/v) gelatin solution in water, derived from bovine skin (Type B; #G1393, 21 
Sigma-Aldrich, UK), was used for biomaterial-based cell ejection studies. 22 
 23 
 Assessing cell recovery and proliferation using PrestoBlue™ 24 
Since cell dose recovery results determined using PrestoBlue were previously shown to be comparable 25 
to the DNA-based Cyquant assay for determination of cell numbers ejected through Hamilton syringes 26 
[28], PrestoBlue™ (Invitrogen Life Sciences, Paisley, UK) was used to determine 24-hour viability 27 
following ejection of cell suspensions (7x105 cells/mL), as well as proliferation over several days. 28 
PrestoBlue™:culture medium (1:9) mixture was added to each well, and incubated in the dark at 37°C 29 
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for one hour. Triplicate 100 µL aliquots were measured for fluorescence on a Tecan Infinite 1 
M200 microplate reader (Tecan, Reading, UK) at λexc/λem of 560/590 nm respectively. 2 
 3 
 Multiplexing quantitative differentiation assays with nuclear staining 4 
Multiplexing of cell-specific differentiation assays and nuclear staining allowed for normalisation to cell 5 
number. After differentiated cells were stained with the OsteoImage™ Staining Reagent, 100 µg/mL 6 
RNase A solution (AppliChem, Darmstadt, Germany) in Tris-EDTA buffer solution (Sigma-Aldrich, UK) 7 
was added for ten minutes at room temperature. Nuclear staining was carried out using 2 µg/mL PI 8 
(diluted in H2O from 1 mg/mL; ThermoFisher Scientific, UK) for 5 minutes. For quantitation, the mean 9 
fluorescence intensity of each well was determined using multiple readings of each well at λexc/λem: 10 
490/530 nm for OstoImage (>64 readings/well) and 535/617 nm for PI (100 readings/well). For 11 
quantification of adipogenesis, differentiated cells were stained with AdipoRed™ Assay Reagent 12 
(Lonza, Germany). Nuclear staining in adipogenic analysis was carried out using 2 µg/mL Hoechst 13 
33258 (diluted in H2O from 1 mg/mL; Sigma-Aldrich, UK) for 15 minutes. The mean fluorescence 14 
intensity of each well was determined using 100 readings per well. 15 
 16 
 Rheological analysis of biomaterial-based carriers 17 
Rheological assessment was carried out using a Physica MCR301 rheometer (Anton Paar, UK) using 18 
rotational and oscillatory measurements. A 50-mm diameter cone-plate (CP 50-1) was used, except for 19 
thixotropy recovery studies which were performed using a PP 25 parallel plate, with a 0.2 mm measuring 20 
gap. All measurements were carried out at a controlled temperature of 25°C. Samples were allowed to 21 
equilibrate for at least 2 minutes prior to analysis. A minimum of three independent measurements were 22 
obtained for each sample, and the average value was reported. Viscosity was determined using a 23 
constant shear rate of 1 s−1.. The average value of all readings at 6 sec intervals over a span of 120 secs 24 
was taken as the viscosity measurement. Steady shear rheology was performed with shear rate varying 25 
from 0.01 to 1000 s−1. Viscometric thixotropy testing was carried out by applying a high magnitude strain 26 
(10000 s-1) to break the biomaterial’s structure, followed by a low level strain (1 s-1) to observe the rate 27 
and extent of recovery of carrier bulk properties. Samples were also subjected to oscillatory strain 28 
sweeps from 0.1-1000% performed at 6 rad/s to assess the failure strain for these materials.  29 
 30 
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 Contact angle measurement 1 
Contact angles of the carriers with glass were measured using the sessile drop method. Soda-lime glass 2 
slides were used for measuring contact angles, which have similar wettability and surface tension in air 3 
to borosilicate glass surfaces of syringes [39]. Contact angles were measured with a CAM 200 4 
instrument (KSV Instruments, Finland) after 10 seconds spreading time. A drop of the material to be 5 
tested was formed on the end of a precision syringe and placed onto the glass slide. Ten images of the 6 
drop were taken at 1-second intervals. All measurements were made at 25°C. The contact angle was 7 
calculated for each image using a Young-Laplace curve fit using the CAM 200 image analysis software, 8 
and resulting right and left contact angles were averaged. A minimum of five repeat measurements were 9 
made for each material using separate glass slides. 10 
 11 
 Statistical Analysis 12 
Statistical analyses were performed using GraphPad Prism 6 software. Data sets were tested for 13 
normality and suitable tests of comparisons were subsequently chosen. All values reported as mean 14 
value +/- SD, unless stated otherwise. Data was analysed by one-way or two-way analysis of variance 15 
(ANOVA) with Dunnett’s post-hoc test, unless otherwise stated. A p-value of ≤ 0.05 was considered to 16 
be significant. 17 
 18 
3. Results 19 
The first part of this study determined whether initial cell seeding density influenced differentiation 20 
capacity. Previously, we showed that ejection rate affected cell dose delivered and that cell recovery 21 
was negatively impacted by low ejection flow rates [28, 29]. Thus, it was critical to quantitatively assess 22 
the impact of cell dose delivered upon differentiation capacity. The second part of the study assessed 23 
the impact of varying ejection rate on the differentiation behaviour of ejected cells. Lastly, biomaterial-24 
based formulations were selected as candidate biomimetic carriers to maximise hMSC recovery at low 25 
ejection rates and investigate the differentiation behaviour of ejected cells.  26 
 27 
 Impact of initial cell seeding density on differentiation potential of hMSCs 28 
Hydroxyapatite deposition was used as a marker of osteogenic differentiation of hMSCs. Supplemental 29 
Figure 2 (A and B) show no significant difference in osteogenic differentiation between the various cell 30 
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numbers initially seeded, as shown by amounts of hydroxyapatite deposited and normalised mineral 1 
deposition to cell number (p<0.05). All cell densities exhibited similar final cell numbers at day 21, with 2 
lower initial cell seeding densities exhibiting a significantly higher fold change in cell number relative to 3 
day 0 (p<0.05) when expressed as fold change in cell number relative to the number of cells initially 4 
seeded (Supplemental Figure 2C). There was no significant difference in the osteogenic differentiation 5 
of different cell seeding densities, as shown by fluorescence microscopy images of hydroxyapatite bone 6 
nodules (Supplemental Figure 2D).  7 
 8 
In contrast to this, there was a clear correlation between initial seeding density and adipogenesis, as 9 
shown by AdipoRed staining and statistically significant differences in normalised fluorescence data 10 
relative to the full seeding density of 7 x 105 cells per well (p<0.05, Supplemental Figure 3A & B). The 11 
dependence of adipogenesis on initial cell seeding density is also shown in Supplemental Figure 3C, 12 
where fluorescence microscopy images demonstrate an increasing intensity of fluorescent staining of 13 
intracellular lipids with increasing initial cell seeding numbers.  14 
 15 
It was therefore chosen to focus on osteogenesis for subsequent studies as a model of differentiation 16 
to investigate the impact of ejection rate on differentiation of ejected hMSCs, since mineralisation at day 17 
21 was shown to be independent of initial cell seeding density.  18 
 19 
 Ejection rate influenced osteogenic differentiation of ejected hMSCs  20 
Directly plated control and ejected samples showed mixed populations of both adipocytes and 21 
osteoblasts. Samples ejected at 10 µL/min exhibited visibly less cells exhibiting the adipocyte 22 
morphology compared to other samples. In addition, brighter OsteoImage staining of hydroxyapatite 23 
(HA) was evident in the samples ejected at 10 µL/min relative to directly plated controls and other ejected 24 
samples (Figure 1A). All ejected samples gave similar absolute fluorescence values when stained with 25 
OsteoImage (Figure 1B); samples ejected at 10 µL/min exhibited lower cell numbers at day 21 relative 26 
to the control (Figure 1C). However, samples ejected at 10 µL/min exhibited statistically significant 27 
higher normalised fluorescence values (Figure 1D), compared to the directly plated control at 21 days 28 
(p<0.05). 29 
 30 
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 Biomaterial-based delivery systems enhanced cell dose recovery and viability 1 
As retention in the delivery device and shear stress may result in a lower number of viable cells 2 
delivered, it was hypothesised that co-injecting cells with biomaterial-based carriers may improve 3 
recovery. Collagen type I, gelatin, bone decellularised ECM (bECM), and high viscosity CMC were 4 
selected to test this hypothesis. Incorporating cells in a protective viscous medium improved cell delivery 5 
(Figure 2A). Cells suspended within 2% gelatin type B exhibited the best recovery, with a signiﬁcantly 6 
improved percentage of viable cells of 87.5 ± 14.1% compared to 32.1 ± 19.1% of the dose delivered 7 
when ejected with PBS. Relative to gelatin and CMC, delivery with collagen and bECM provided 8 
significantly lower percentages of viable cells with 53.4 ± 24.4% and 60.7 ± 10.1% respectively 9 
delivered. To investigate the effect of using a lower concentration of the same material, two 10 
concentrations of CMC (0.5% and 0.25% (w/v)) were compared (Figure 2B). The lower concentration 11 
(0.25% (w/v)) CMC resulted in a significantly lower percentage of the dose being delivered as viable 12 
cells (p=0.05). 13 
 14 
Live/Dead staining revealed a high proportion of viable cells among all cell carriers investigated (Figure 15 
2C). However, a visibly lower number of cells appeared in ejected samples suspended in PBS compared 16 
with other carriers. Brightfield images of the ejected samples 24 hours post-ejection (Figure 2D) 17 
displayed an obvious presence of fibril-like structures in samples ejected within collagen and bECM; 18 
cells ejected within other carriers did not display fibrillogenesis. These fibrils were not stained by calcein 19 
(Figure 2C). The proliferative ability of ejected hMSCs was not significantly affected by choice of cell 20 
carrier, with similar fold changes in cell numbers observed at day 10 relative to the control (Figure 2E).  21 
 22 
 Characterisation of biomaterial-based carriers  23 
The rheological properties and surface tension of the carriers were characterised to elucidate the effects 24 
of material properties upon cell behaviour. Gelatin displayed the lowest viscosity (0.01 ± 0.0007 Pa.s) 25 
and collagen the highest (0.66 ± 0.11 Pa.s) (Figure 3A). The steady shear rheological properties of the 26 
carriers are presented in Figure 3B. bECM, gelatin and collagen showed more significant shear-thinning 27 
profiles (Δη ~104 Pa.s) than both concentrations of CMC (Δη ~ 102 Pa.s). Collagen had a viscosity of 28 
around 150 Pa.s at a shear rate of 0.01 s-1, shearing down to 0.001 Pa.s at 1000 s-1. Gelatin exhibited 29 
a viscosity of around 1 Pa.s at 0.01 s-1, shearing down to 0.002 Pa.s at a shear rate of 1000 s-1, and not 30 
crossing over the profiles of both CMC concentrations.  31 
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 1 
A viscometric 3-step thixotropy test was carried out to investigate recovery of material properties (Figure 2 
3C). CMC and collagen showed fast and complete recovery within seconds. Gelatin recovered its 3 
viscosity within a few seconds to almost 90% of its initial value, but started breaking down 70 seconds 4 
following strain removal. bECM showed a more gradual recovery to almost 65% of its original properties 5 
at 180 seconds following strain removal. Due to their shear-thinning and self-healing properties, all 6 
carriers investigated were shown to be injectable through a clinically-relevant 30G needle (Figure 3D). 7 
 8 
All cell carriers employed in this study, except CMC, showed higher storage moduli than loss moduli, 9 
with curves being parallel and almost linear, which confirmed their hydrogel nature. However, CMC 10 
displayed a higher G′′ than G′, and should therefore be classified as a viscous carrier or viscosity 11 
modifying excipient. All carriers displayed broad linear viscoelastic regions (Supplemental Figure 4). 12 
Collagen and bECM exhibited failure of the gel structure at high strains of around 65% and demonstrated 13 
strain stiffening behaviour. 14 
 15 
All biomaterials exhibited water contact angles ranging from 18° to 35° (Supplemental Figure 4). PBS, 16 
collagen and bECM were the most hydrophilic; PBS had the lowest contact angle of 18.6 ± 3.0°, while 17 
collagen was less hydrophilic, with a contact angle of 24.0 ± 2.7°. Gelatin was the least hydrophilic 18 
among the biomaterials investigated, with a contact angle of 34.3 ± 5.0° (Supplemental Figure 4B). The 19 
more dilute concentration (0.25%) of CMC exhibited a lower contact angle of 29.0 ± 5.8°, compared to 20 
33.4 ± 4.1° for the higher concentration of 0.5% (Supplemental Figure 4C).  21 
 22 
 Impact of biomaterial-based cell carriers upon differentiation capacity of hMSCs 23 
All directly plated control and ejected hMSCs underwent osteogenic differentiation after 21 days of 24 
culture in bipotential medium (Figure 5). All samples exhibited a mixed population of cells displaying 25 
typical adipocyte morphology as well as mineralised bone nodules. PBS-ejected samples consistently 26 
displayed visibly lower numbers of cells exhibiting adipocyte morphology, in addition to some cells 27 
displaying a fibroblast-like morphology typical of undifferentiated MSCs. Whilst fluorescence images 28 
indicated that all control and ejected samples exhibited mineralisation, a notably higher extent of calcium 29 
and hydroxyapatite deposition was observed in samples ejected within collagen and bECM compared 30 
to the control and other carriers. Quantitative assessments of hydroxyapatite deposition (Figure 6A) 31 
14 
 
confirmed that cells co-ejected within collagen, bECM and gelatin led to significantly enhanced 1 
mineralised content relative to samples ejected within PBS. However, all samples exhibited no 2 
significant difference in normalised fluorescence values (Figure 6B). 3 
 4 
To determine whether ejection forces and biomaterial-based delivery had a synergistic effect upon 5 
mineralisation, hydroxyapatite deposition was compared in cells suspended within collagen and bECM, 6 
either directly plated in 12 well-plates (referred to as “plated”) or ejected at 10 μL/min (“ejected”). 7 
Samples were directly plated at 60% of the initially ejected cell number within each carrier material to 8 
account for the loss of cells during ejection and to preclude any potential influence of initial seeding 9 
density (Figure 2A). As shown in Figure 6C & D, there was no significant difference in hydroxyapatite 10 
deposition between the directly plated and ejected cells within collagen and bECM at day 21, both in 11 
terms of absolute and normalised values.  12 
 13 
To determine if ALP was released into the media as a result of shear stress exposure, culture media 14 
were assayed following induction of differentiation. At day 2, media ALP activity was generally higher in 15 
ejected hMSCs compared to directly plated samples. Ejection within PBS and bECM increased released 16 
ALP activity compared with directly plated hMSCs (Figure 6E, p<0.05). To determine whether ejection 17 
forces and biomaterial-based carriers had a synergistic effect upon released ALP, media ALP levels in 18 
plated versus ejected cells, suspended within collagen or bECM, were compared. Figure 6F shows 19 
increased media ALP levels in ejected samples relative to plated ones within collagen and bECM. 20 
 21 
Although total cellular ALP activity was significantly lower for hMSCs ejected within PBS than for control 22 
samples at day 2 (Supplemental Figure 5A), normalised levels of ALP production was similar for all 23 
samples tested at this time point (Supplemental Figure 5B). Expression of normalised cellular ALP 24 
generally peaked earlier (day 4) for directly plated samples compared to ejected samples (day 7). To 25 
explore whether shear forces contributed to ALP expression pattern, directly plated and ejected hMSCs 26 
within bECM and collagen carriers were compared. The same pattern of normalised ALP levels peaking 27 
earlier (at day 4) in directly plated samples relative to ejected samples was observed (Supplemental 28 
Figure 5C) and no significant differences in DNA content (Supplemental Figure 5D). After 21 days, 29 
immunostaining for OCN showed a robust expression of this late osteogenic marker across all samples 30 
after 21 days of culture (Supplemental Figure 5E).  31 
15 
 
 1 
4. Discussion 2 
Since previous work demonstrated that cell ejections at slower flow rates resulted in lower percentages 3 
of the cell dose being delivered [28, 29], experiments were carried out first to investigate the dependence 4 
of differentiation capacity on initial cell number using bipotential media. In typical monopotential 5 
differentiation media, two different variables may act to direct hMSCs down a certain differentiation 6 
pathway: biochemical-based induction or effects of exposure to mechanical forces of ejection. Deducing 7 
the impact of physical cues on cell differentiation fate is difficult to explore within the chemically defined 8 
environments of monopotential differentiation media. By using ‘mixed’ media, a bipotential setting was 9 
provided whereby the appropriate chemical differentiation cues required for both osteogenesis and 10 
adipogenesis were available. This allowed us to study the impact of physical cues, such as mechanical 11 
forces or cell carrier, on cell lineage fate independent of chemical dosing variables. 12 
 13 
 Impact of cell seeding density on differentiation capacity of hMSCs 14 
No statistically significant differences were detected in hydroxyapatite deposition at the initial seeding 15 
densities under investigation. Thus, we postulated that the different initial cell seeding numbers resulting 16 
from the various ejection rates tested had  negligible effects on mineralisation at day 21, even at the 17 
lowest flow rate under investigation (~35% of cell dose is delivered at 10 µL/min [28]). These results are 18 
consistent with findings from studies carried out on various scaffolds, which demonstrated that higher 19 
seeding densities do not necessarily produce enhanced proliferation and differentiation [40, 41]. Holy et 20 
al. investigated the effect of initial seeding density upon rat bone marrow-derived cell differentiation on 21 
PLGA scaffolds and showed that final mineralised tissue formation was independent of initial seeding 22 
density [42].  23 
 24 
When cell numbers at day 21 were expressed as fold change in cell number to initial cell seeding 25 
number, it was found that lower seeding densities corresponded to the highest proliferation, which 26 
agrees with previous studies by McBeath et al. [43]. In contrast to the effect on the osteogenesis marker 27 
quantified, adipogenic differentiation capacity was influenced by cell seeding number. This result is in 28 
line with previous findings [43, 44]. As mineralisation at day 21 was shown to be independent of initial 29 
cell seeding density, osteogenesis was selected as the model for this study. Osteogenesis is a robust, 30 
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well-established in vitro cellular model of differentiation in hMSCs with well-defined assays and 1 
measurable outputs [45].  2 
 3 
 Ejection rate influenced osteogenic differentiation capacity of ejected hMSCs 4 
Since we established that the different cell numbers ejected at different rates did not influence total 5 
mineralisation levels nor normalised mineralisation-to-cell-number values at day 21, we moved on to 6 
investigate the impact of ejection rate on the osteogenic differentiation capacity of ejected hMSCs. 7 
 8 
Exposure of MSCs to shear stress, whether controlled (fluid flow) or uncontrolled (flow perfusion), has 9 
been reported to result in enhanced osteogenic matrix production and maturation [46-48]. Previous work 10 
has qualitatively demonstrated that mesenchymal stem cells ejected at 10 µL/min resulted in 11 
considerably lower osteogenic differentiation capacity [28], but no further investigation was carried out. 12 
Normalised mineralisation values of cells growing in the bipotential differentiation environment showed 13 
a significantly higher level of mineral deposition per cell at the lowest flow rate (10 µL/min) relative to 14 
control (Figure 1B). This suggests that hMSCs ejected at this rate either preferentially underwent 15 
osteogenic differentiation relative to the other samples, started differentiating earlier, or had enhanced 16 
osteogenic efficiency per cell. These differentiation trends confirmed that prolonged exposure to the 17 
mechanical forces generated at 10 µL/min, rather than cell density and associated cell-cell interactions, 18 
influenced the differentiation fate of ejected cells. 19 
 20 
 Biomaterial-assisted delivery 21 
The development and evaluation of convenient, cost-effective and efficient cell delivery systems will aid 22 
the translation of cell-based therapies to the clinic. This study explored whether the use of naturally-23 
derived biomaterials will influence cellular differentiation and potentially stimulate endogenous 24 
regeneration, acting as instructive cell delivery platforms. This study investigated the effects of using 25 
various natural biomaterial-based cell carriers for ejection of hMSCs on cell dose recovery, commitment 26 
and differentiation capacity in a clinically relevant syringe/needle ejection scenario. The choice of 27 
biomaterials reflects our aim to achieve simple, reproducible, and clinically relevant delivery of hMSCs 28 
to facilitate low-dosage cell therapies.  29 
 30 
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Since there are unavoidable delays in any clinical cell delivery procedure, cell carriers may provide 1 
physical and chemical cues within this time that would inevitably direct cell functionality outcomes, such 2 
as proliferation and differentiation. Within biomaterials, cues may include material composition as well 3 
as external physical cues resulting from the exposure of cells to mechanical forces associated with 4 
injection procedures. Materials utilised in this study were chosen to be readily available, customisable, 5 
user-friendly, and easily injectable through clinically-relevant needles. Since ECM, composed mainly of 6 
proteoglycans, glycosaminoglycans and fibrous proteins (e.g.: collagen), provides key biochemical and 7 
biomechanical cues required for tissue differentiation and homeostasis [49], materials were also 8 
selected based on major components of the ECM. Protein-based polymers have the advantage of 9 
mimicking characteristics of the natural ECM, and thereby the potential to impact the growth and 10 
organisation of transplanted cells [24]. Collagen type I, for example, has been widely applied as scaffolds 11 
for cell delivery, including animal models of brain injury, with good biocompatibility [50, 51]. Similarly, 12 
gelatin is a hydrolysed form of collagen [52] with biomechanical similarity to the ECM [53]. The 13 
supplementation of algal cultures with CMC, as a modifier of interfacial properties, has been reported to 14 
protect algal cells against hydrodynamic stress [54]. 15 
 16 
Results revealed that utilising injectable hydrogels and viscosity modifying excipients for cellular delivery 17 
demonstrated positive effects on cell recovery (Figure 2). A significant loss of cells at 10 µL/min was 18 
observed in unprotected (PBS) samples at 24 hours post-ejection. Gelatin (protein-based) and CMC 19 
(polysaccharide-based) cell carriers displayed the highest percentage of viable cells delivered, with no 20 
significant difference to directly plated samples. In comparison, collagen and bECM carriers (both 21 
protein-based) resulted in lower cell recovery, yet significantly better than ejecting within PBS. An 22 
improvement in cell viability post-ejection was previously obtained by Aguado et al. using alginate gels 23 
via a 28G needle [10], which had been suggested to be due to plug ﬂow, whereby the hydrogel adjacent 24 
to the walls undergoes shear thinning and forms a ﬂuid layer which acts as a lubricant [55]. This 25 
lubricating fluid layer may be one explanation for the higher percentages of the cell doses delivered in 26 
this study through keeping the cells in the central plug zone away from the walls. The significant 27 
improvement in cell dose recovery demonstrated herein, in clinically relevant narrow-bore needles at 28 
low ejection rates used in clinical trials [35, 56], may be vital to cells that display biological changes after 29 
exposure to mechanical forces. 30 
 31 
18 
 
Live/Dead staining confirmed that all tested carriers conserved a high degree of viability of ejected cells. 1 
Microscopy revealed a dilute meshwork of what appears to be collagen fibrils dispersed between cells 2 
in samples ejected within collagen and bECM, since they were not stained by calcein. Solubilised 3 
collagen I can be mixed with living cells during gelation to implant cells in a fibrillar collagen matrix. The 4 
force generation and properties of collagen fibrils are comparable to biological filaments, such as actin 5 
or microtubules [57]. Non-covalent inter-fibril network interconnections have been reported to transmit 6 
cellular traction forces [58]. This may have given rise to extracellular cues that affected cell fate in 7 
samples ejected within collagen and bECM relative to hMSCs ejected within PBS. Co-delivery of the 8 
cells within the biomaterials studied showed that cells remained viable in vitro ten days post-ejection. 9 
 10 
Cell dose recovery did not correlate with the biochemical nature of the polymer (protein- versus 11 
polysaccharide-based), so rheological studies were carried out to investigate possible correlation of cell 12 
recovery with mechanical properties of the biomaterials. Shear-thinning behaviour of these biomaterials, 13 
showing a relatively large change in the viscosity (Δη ~ 102 - 104 Pa.s) from low (0.01 s−1) to high (1000 14 
s−1) shear rates, is a beneficial property for injection-based delivery through narrow-bore needles. 15 
Viscometric thixotropy testing revealed that biomaterials were able to recover after shearing, with some 16 
biomaterials (collagen and CMC) exhibiting more complete recovery than others. Oscillatory shear 17 
rheology of the biomaterials also showed that some of the softer materials with lower storage moduli 18 
(G’), such as CMC and gelatin, resulted in better cell recovery than collagen, which has a storage 19 
modulus that is ten-fold higher. However, rheological data was not sufficient to explain the significant 20 
improvement of cell recovery with gelatin and CMC carriers relative to collagen and bECM. Gelatin and 21 
0.25% CMC, for example, displayed similar storage moduli (Supplemental Figure 4), yet showed 22 
significantly different cell dose recovery rates. In addition, viscosities and shear-thinning profiles of the 23 
two concentrations of CMC under investigation (0.5 and 0.25%) were not significantly different, thereby 24 
not explaining the significant difference in dose recovery between them. Therefore, focusing on the 25 
rheological properties of a carrier to determine its efficacy at delivering the required number of viable 26 
cells is not sufficient. 27 
 28 
Surface wettability can influence protein adsorption and, in turn, initial cell attachment. Gelatin resulted 29 
in high contact angles on glass despite being structurally similar to collagen due to the preferred 30 
orientation of hydrophobic moieties at the air-gel interface, causing a specific arrangement of water 31 
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molecules [59]. Cell adhesion is similar to physical adhesion in that the cell membrane must make close 1 
molecular contact with the surface [60], and therefore we hypothesised that greater levels of cell 2 
attachment occurred with surfaces of high wettability since cells can make close contact with these 3 
surfaces. Some studies have shown that hydrophilic surfaces produced a significant increase in the 4 
amount of protein adsorption, a high initial rate of cell attachment [61, 62], and generally better cell 5 
adhesion [63]. It has also been reported that cells adhered and proliferated more on surfaces with 6 
moderate hydrophilicity than on the more hydrophobic or hydrophilic spots [64]. Improvement of cell 7 
attachment with decreasing contact angles has been observed at incubation times of up to 60 minutes 8 
[62]. The cell carriers with the lowest glass surface wettability in this study displayed the best cell dose 9 
recovery. This may be due to the lower contact that these carriers provide with the glass surface of the 10 
syringe, discouraging adhesion during the time spent in the delivery device.  11 
 12 
Cell recovery trends appeared to correlate with the contact angles displayed by the various carriers, 13 
whereby materials displaying the highest contact angles also displayed the highest percentage of cell 14 
dose recovered (Figures 2A and 4B). Moreover, cell recovery did not appear to correlate with the shear-15 
thinning properties of the biomaterials under investigation, as suggested by previous studies [10, 55]. 16 
Collagen, for example, showed the best shear-thinning properties, yet the lowest percentage of cell dose 17 
recovery between the biomaterials tested. The ability of cells to attach to a surface will depend on the 18 
cell type and surface used. Further experiments comparing the attachment of different cell types, syringe 19 
material surfaces and a wider range of surface wettability values is required to determine the generality 20 
of this observation and make use of it to design more efficient cell delivery systems.  21 
 22 
A cell’s fate is tightly regulated by its microenvironment, since cells commit to their fate by deriving 23 
information from their surroundings [65]. ECM proteins are recognised by cell surface receptors and are 24 
involved in cell processes such as proliferation and differentiation. For example, hyaluronan (HA), a 25 
naturally occurring polysaccharide found in the ECM of the central nervous system (CNS), can interact 26 
with various HA-receptors present on diverse cell types to promote cell adhesion and survival [66]. 27 
Therefore, it was hypothesised that biomimetic protein-based cell carriers may have a discernible impact 28 
on cell commitment and differentiation capacity. Late stage osteogenic differentiation was enhanced by 29 
the protein-based cell carriers, namely collagen, bECM, and gelatin, as demonstrated by the 30 
mineralisation results. The higher mineralisation levels in samples ejected within collagen (p<0.01) 31 
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compared to control samples at day 21 suggested that the use of a biomimetic cell carrier for the desired 1 
cell type can enhance differentiation response significantly. Fibril-forming collagen type I forms more 2 
than 90% of the organic mass of bone [67]. Bone marrow MSCs have been reported to undergo 3 
osteogenesis when cultured on collagen I matrices in vitro by interaction with the COL-I-binding 4 
integrin α2β1 [68]. One study hypothesised that adhesion to ECM proteins, in the absence of soluble 5 
osteogenic stimulants, can act as insoluble cues of osteogenesis [69]. Given the tissue specificity of 6 
ECM and the abundant presence of collagen in bone-derived ECM [70], these protein-based 7 
biomaterials have the potential of mimicking native bone microenvironment pre-injection and closely 8 
mirror the target site once injected [71]. Since a bipotential differentiation environment was used in this 9 
study, it could be hypothesised that overall mineralisation was enhanced due to a higher number of cells 10 
being directed towards an osteogenic lineage, such as in ECM (high total mineralisation but similar 11 
normalised mineralisation levels per cell), and on a ‘mineralisation per cell’ basis in the case of PBS (low 12 
total mineralisation but trending towards higher normalised mineralisation levels relative to control). 13 
There was no significant difference in hydroxyapatite deposition between directly plated and ejected 14 
cells within collagen and bECM at day 21, suggesting that the more extensive mineralisation observed 15 
with these carriers relative to PBS is not augmented by mechanical forces encountered by the cells 16 
during ejection. 17 
 18 
ALP is widely used as an indicator of osteogenic commitment, and commonly precedes bone matrix 19 
mineralisation [72, 73]. Significantly higher levels of ALP released into the media was observed in the 20 
unprotected samples ejected within PBS relative to directly plated ones. There was also a notable trend 21 
of increased media ALP levels in ejected samples relative to directly plated ones within the same bECM 22 
carrier. A similar result was previously obtained by Yourek et al., whereby 24 hr exposure to shear stress 23 
resulted in higher ALP activity in the media than in control cells [74]. Results of cellular ALP analysis 24 
may be due to mechanical forces caused by the ejection process, resulting in the slower commitment 25 
of ejected cells towards the osteogenic lineage in vitro (in comparison to direct plating), but stronger 26 
osteogenic expression. This is implied by later peaking of normalised ALP expression in ejected samples 27 
at day 7, and enhanced mineralisation results with cells ejected within protein-based carriers at day 21. 28 
Results suggest that although shear stress in combination with collagen-based carriers supported 29 
osteogenic differentiation more effectively relative to the plated control, the commitment process took 30 
longer. Correspondingly, Grellier et al. exposed hMSCs to short periods of fluid shear stress and showed 31 
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that 30 min exposure upregulated ALP mRNA but 90 min decreased it to almost basal levels [75]. 1 
Moreover, MSCs exposed to oscillatory fluid flow displayed reduced ALP activity despite upregulating 2 
OCN mRNA under the same conditions [76]. Osteogenic differentiation is complex and multifactorial, 3 
and the detailed mechanism of how ALP acts is unclear [77]. Further studies are needed to explore the 4 
impact on differentiation in more detail, since it is reasonable to believe that injectable delivery may 5 
impair cells’ ability to differentiate into the required cell type, or cause differentiation into other 6 
undesirable cell types. 7 
 8 
5. Conclusions 9 
This study demonstrated that the use of natural, low viscosity biomaterials as cell carriers is an efficient 10 
approach to significantly improve the percentage of the cell dose delivered relative to the commonly-11 
used saline cell vehicle, enabling the administration of low-dosage cell therapies through narrow, 12 
clinically-relevant needles. This improvement in cell dose recovery was not associated with the 13 
rheological properties of the biomaterials utilised, as had been suggested by previous studies.  14 
 15 
Moreover, the extent of differentiation in hMSCs, as demonstrated through the use of osteogenesis as 16 
a model of stem cell differentiation, was shown to be substantially altered by the selection of biomaterial 17 
carrier, despite limited contact time of the carrier with ejected cells during delivery, as well as ejection 18 
rate. The development of tailored biomaterial-assisted cell delivery systems for the desired application 19 
will accelerate clinical translation of cell-based therapeutics and allow the utilisation of biomaterials for 20 
more efficient cell delivery and potentially directing stem cell fate. 21 
 22 
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 5 
Figure Legends 6 
Fig. 1: Effect of ejection rate on osteogenic differentiation capacity of hMSCs ejected via 30G 7 
needles, cultured in bipotential osteogenic/adipogenic media for 21 days. (A) Representative 8 
bright field and fluorescence microscopic images showing ejected hMSCs after culturing in bipotential 9 
media. Cell nuclei are stained red (PI), while mineralised areas are stained green (OsteoImage). 10 
Intracellular lipid accumulation is indicated by arrows (Scale bar = 100µm). (B) OsteoImage fluorescence 11 
values for ejected hMSCs at day 21. Each bar represents mean fluorescence values ± SD (n = 9 in three 12 
independent experiments and two donors). (C) Number of cells at day 21 quantitated using PI staining 13 
of hMSCs from two donors. (mean ± SD, n = 6). Asterisks represent statistically significant difference 14 
from directly plated control using ANOVA and Dunnet’s post-hoc test; *p≤0.05, ***p≤0.001; 15 
Unind=Uninduced. (D) OsteoImage fluorescence readings were normalised to cell count, based on PI 16 
staining (mean ± SD, n = 6). 17 
 18 
Fig. 2: Cell recovery, viability and proliferation after ejecting hMSCs suspended in various 19 
carriers via 30G needles at 10 µL/min. (A) Proportion of hMSCs delivered, measured using 20 
PrestoBlue, within phosphate buffered saline (PBS), carboxymethyl cellulose (CMC), gelatin (Gel), type 21 
I collagen (Coll) and bone extracellular matrix (ECM). Data represents averages from three donors in 22 
five independent experiments (n=5; mean ± SD). Data were normalised against control value of directly 23 
plated cells. (**p≤0.01, ****p≤0.0001 - one-way ANOVA with Dunnett’s post-hoc test). (B) Percentage of 24 
cell dose delivered as viable cells when ejected at 10 µL/min via 30G needles when suspended within 25 
two concentrations of CMC (0.5% and 0.25%). Data represents averages from two donors (n=3; mean 26 
± SD). Data were normalised against control value of directly plated cells. Asterisks indicate statistically 27 
signiﬁcant differences between numbers of ejected cells compared with control (*p=0.05 - One-way 28 
ANOVA with Kruskal-Wallis analysis). (C) Representative Live/Dead-stained fluorescence images of 29 
hMSCs 24 hours following ejection at 10 µL/min, using various biomaterials as cell carriers (Scale 30 
bar=100 μm). (D) Representative brightfield images showing morphology of ejected hMSCs cultured for 31 
27 
 
24 hrs post-ejection. Bundles of fibrils surrounding the ejected cells are depicted by arrows (Scale 1 
bar=50 μm). (E) Proliferation of hMSCs given as fold change in number from day 1 of each sample, 2 
measured using PrestoBlue (mean ± SD; n=4, measured in two donors). 3 
 4 
Fig. 3: Rheological characterisation of biomaterial-based cell carriers employed in this study. (A) 5 
Viscosities of the carriers were determined at 25°C with a constant shear rate of 1 s-1 (mean ± SD; n=3). 6 
(B) Shear thinning properties of different carriers employed shown by steady shear rheological 7 
measurements. (C) Viscometric 3-step thixotropy test to display structure recovery of the hydrogel 8 
immediately after disruption due to a high-magnitude shear-rate strain (10000 s-1), followed by a low 9 
magnitude strain (1 s-1) to monitor recovery of bulk properties. (D) Figure shows 0.5% CMC ejected 10 
through a 30G needle, as a representative of injectability of biomaterials investigated. 11 
 12 
Fig. 4: Measurement of contact angles of biomaterial-based cell carriers on a glass surface. (A) 13 
Contact angle images of various biomaterials employed on soda-lime glass slides measured at room 14 
temperature. (B, C) Measurement of contact angles of various carriers on a soda-lime glass surface. 15 
Each bar represents the mean ± SD (n = 5; **p<0.01; ***p<0.001; relative to PBS). 16 
 17 
Fig. 5: Representative brightfield and fluorescence microscopy images displaying the qualitative 18 
assessment of osteogenic differentiation capacity of hMSCs post-ejection, after culturing in 19 
bipotential ‘mixed’ media for 21 days. To assess the degree and distribution of mineralisation of the 20 
extracellular matrix, the last stage of osteogenesis, samples were observed using dissection and 21 
brightfield microscopy (10x), in addition to staining with Alizarin Red S (10x) and OsteoImage/PI (5x). 22 
Cells exhibiting typical adipocyte morphology are depicted in brightfield microscopy images using arrows 23 
(Scale=50 µm). Red represents calcium deposition, stained using Alizarin Red, and green depicts 24 
hydroxyapatite nodules stained using OsteoImage. 25 
 26 
28 
 
Fig. 6: Impact of biomaterial-based carriers on osteogenic differentiation markers of hMSCs 1 
ejected via 30G needles, cultured in bipotential media for 21 days. (A) OsteoImage fluorescence 2 
values, showing hydroxyapatite formation. Each bar represents mean fluorescence value ± SD, n = 6 in 3 
3 donors. Asterisks represent statistically significant difference relative to PBS using ANOVA and 4 
Dunnet’s post-hoc test (*p≤0.05; **p≤0.01). (B) OsteoImage fluorescence intensity readings in were 5 
normalised to PI-based cell counts (mean ± SD, n = 6). (C) Ejected vs directly plated hMSCs, suspended 6 
within collagen and ECM, assessed for osteogenic differentiation capacity. “Ejected” cells were ejected 7 
at 10 µL/min, and “plated” cells were 60% of ejected cell number directly plated in 12-well plates. Results 8 
are mean fluorescence values ± SD, n = 4 in 2 donors (D) OsteoImage fluorescence intensity readings 9 
in (C) were normalised to PI-based cell counts (mean ± SD, n = 4; 2 donors). (E) Media alkaline 10 
phosphatase activity levels of hMSCs ejected at 10 µL/min, via 30G needles, were cultured in bipotential 11 
osteogenic/adipogenic media for 2 days after adding differentiation media 24 hrs post-ejection. Values 12 
shown are mean ± SD (n=3; 2 donors). Asterisks indicate statistically significant differences in ALP 13 
levels relative to control (Friedman test with Dunn’s post-hoc; *p<0.05). (F) Released ALP levels in 14 
ejected versus directly plated hMSCs suspended within collagen and ECM. “Ejected” cells were ejected 15 
at 10 µL/min, and “plated” cells were 60% of the initially ejected cell number directly plated in 12-well 16 
plates. Results are mean fluorescence values ± SD (n = 4 in 2 donors). 17 
 18 
 19 
Additional Files 20 
Name: Suppl fig 1 21 
Format: .pdf 22 
Title: Supplemental Figure 1 23 
Description:  24 
Schematic presentation of the methodology used to explore the effects of various cell carriers on hMSC 25 
delivery. Efficacy of delivery, in terms of cell recovery, viability and proliferation capacity, was assessed. 26 
In addition, various parameters of osteogenic differentiation were measured to determine the potential 27 
impact of various cell carriers on osteogenic differentiation capacity. 28 
29 
 
 1 
Name: Suppl fig 2 2 
Format: .pdf 3 
Title: Supplemental Figure 2 4 
Description:  5 
Effect of initial cell seeding density of hMSCs on their osteogenic differentiation potential when cultured 6 
in bipotential adipogenic/osteogenic media, quantified based on mineral deposition. (A) OsteoImage 7 
staining for hydroxyapatite in hMSCs from two donors seeded at different initial seeding densities in a 8 
12-well plate, cultured in bipotential media for 21 days (mean ± SD, n=6). No significant difference was 9 
revealed between the various initial cell seeding densities, analysed using one-way ANOVA and Tukey’s 10 
post-hoc test (B) OsteoImage fluorescence readings were normalised to cell count, based on nuclear 11 
staining using PI (mean ± SD, n = 4). Statistical analysis was performed using Kruskal-Wallis test, with 12 
Dunn’s post-hoc test; ns: no significant difference. (C) PI cell counts normalised to the respective initial 13 
cell numbers seeded, expressed as the fold change relative to initial cell seeding density (mean ± SD, 14 
n=4). Data represents averages from two donors; Asterisks indicate statistically signiﬁcant difference 15 
from full seeding density of 70,000 cells/well (*p<0.05 - Kruskal-Wallis test, with Dunn’s post-hoc test). 16 
(D) Representative fluorescence microscopy images of hMSCs at day 21. Nuclei were stained with PI, 17 
and hydroxyapatite was fluorescently stained using OsteoImage (Scale bar=100 µm). 18 
 19 
Name: Suppl fig 3 20 
Format: .pdf 21 
Title: Supplemental Figure 3 22 
Description:  23 
Effect of initial cell seeding density of hMSCs on their adipogenic differentiation when cultured in 24 
bipotential adipogenic/osteogenic media. (A) AdipoRed staining for lipid content in hMSCs seeded at 25 
different initial seeding densities in a 12-well plate, cultured in bipotential media for 21 days (n=4). 26 
30 
 
Asterisks indicate statistically signiﬁcant difference from the full seeding density of 70,000 cells/well 1 
(**p<0.01, *p<0.05 - Kruskal-Wallis test, with Dunn’s post-hoc test). (B) AdipoRed fluorescence 2 
readings, adjusted for cellular count based on nuclear staining using Hoechst 33258 (mean ± SD, n = 3 3 
in triplicates). Statistical analysis was performed using Kruskal-Wallis test, with Dunn’s post-hoc test 4 
(*p<0.05). (C) Fluorescence microscopy images of hMSCs cultured in bipotential differentiation media 5 
at day 21. Lipid droplets were fluorescently stained using AdipoRed Adipogenesis Reagent, after which 6 
nuclei were counter-stained with Hoechst. (Scale bar=100 µm). 7 
 8 
Name: Suppl fig 4 9 
Format: .pdf 10 
Title: Supplemental Figure 4 11 
Description:  12 
Oscillatory rheological measurements of the biomaterial-based carriers to obtain storage (G’) and loss 13 
(G’’) moduli from a strain-amplitude sweep (0.1–1000%) performed at 6 rad/s (n≥3). This was carried 14 
out for (A) 5 (0.5%) and 2.5 (0.25%) mg/mL CMC, (B) 20 mg/mL (2%) gelatin, (C) 1.75 mg/mL collagen, 15 
(D) 1.75 mg/mL bone ECM. 16 
 17 
Name: Suppl fig 5 18 
Format: .pdf 19 
Title: Supplemental Figure 5 20 
Description:  21 
Cellular alkaline phosphatase activity levels of hMSCs at different time points following ejection at 10 22 
µL/min via 30G needles, and cultured in bipotential media. (A) Cellular ALP was analysed 2, 4 and 7 23 
days post-induction. Values shown are mean ± SD (n=3; 2 donors). Asterisks indicate statistically 24 
significant differences in ALP levels relative to control (Friedman test with Dunn’s post-hoc; *p<0.05) (B) 25 
Cellular ALP values normalised to DNA content (mean ± SD; n=3; 2 donors) (C) Normalised cellular 26 
31 
 
ALP levels in ejected versus directly-plated hMSCs suspended within collagen and ECM. “Ejected” cells 1 
were ejected at 10 µL/min, and “plated” cells were 60% of the initial cell number directly plated (mean ± 2 
SD; n = 3 in 2 donors). (D) DNA content of hMSCs in ejected versus directly plated samples suspended 3 
within collagen and ECM (mean ± SD). (E) Representative immunofluorescent staining of human 4 
osteocalcin (OCN) and nuclei counterstained with DAPI (blue) to confirm osteogenic differentiation of 5 
hMSCs. Directly plated and ejected hMSCs (via 30G needles at 10 µL/min), were cultured in bipotential 6 
media at 21 days post-induction (Scale bar = 50 μm). 7 
